SecBot SecBot
144 ·Filed Apr 13, 2026

CGEN

COMPUGEN LTD
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001976408-26-000324
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine, pre-planned sale under a 10b5-1 plan and not an immediate red flag. However, traders should monitor for actual execution around April 10 and watch for additional filings that may indicate broader insider selling trends.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.76
T+0 close · Apr 13, 2026 · via day close
Latest settled
−12.68%
T+60 · $2.41
Vs SPY
−21.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $2.76entry
  2. T+1 · 7mo ago +4.35%α +3.14% · $2.88
  3. T+5 · 7mo ago +4.35%α +1.05% · $2.88
  4. T+20 · 6mo ago +3.99%α −3.74% · $2.87
  5. T+60 · 4mo ago −12.68%α −21.60% · $2.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zurit Levine, an officer of Compugen Ltd, filed a Form 144 to notify intent to sell up to 2,000 ordinary shares, valued at approximately $49,600 based on the current market price. The shares are part of a 10b5-1 sale plan adopted on December 24, 2025, with the proposed sale date on April 10, 2026.

Key Facts

  • Reporting person: Zurit Levine, Officer of Compugen Ltd
  • Number of shares proposed for sale: 2,000
  • Approximate value of shares: $49,600 (based on $24.80/share implied price)
  • Sale planned under a 10b5-1 plan adopted on December 24, 2025
  • Proposed sale date: April 10, 2026
  • Shares originated from the Employee Stock Option Plan, granted August 3, 2023

Financial Impact

Minimal dilution or financial impact; proposed sale of $49,600 worth of shares represents less than 0.02% of Compugen's $244M market cap

equity ownershipinsider持股 concentration

Risk Factors

  • Perception of lack of confidence if multiple insiders initiate similar sales
  • Execution risk if the sale proceeds near-term and adds downward pressure on a low-volume stock

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001976408-26-000324
Document: 0001976408-26-000324-index.html0001976408-26-000324
Document: 0001976408-26-000324.txt0001976408-26-000324

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026